Advestra advised Swiss pharmaceutical company Novartis on all Swiss aspects of its USD 11.0 billion note placement. The notes in question were issued in seven tranches of which six were fixed rate notes while one tranche
Tags :Novartis
Swiss healthcare company Novartis, acting through one of its wholly-owned indirect subsidiaries, completed the acquisition of RNA therapeutics specialist Avidity Biosciences, for a total value of approximately USD 12 bn. In connection with the deal, Homburger
Advestra advised Novartis, as the Basel-based pharma multinational placed notes in the aggregate principal amount of USD 6.0 billion. The issuance featured seven tranches of which six referring to fixed rate notes and one to floating
Karen Hale (pictured) is the new Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. Following the new appointment, Hale will continue to report to Vas Narasimhan, CEO of Novartis, and remain on the Executive
Alejandro Bes (pictured), joins Axmed as its new general counsel, effective today. Alejandro Bes’ career path Bes began his legal career as an associate at Freshfields in Spain. He later transitioned to an in-house role,
Advestra acted as Swiss legal counsel to Novartis, which successfully placed notes in the aggregate principal amount of USD 3.7 billion in four tranches of USD 1 billion 3.800%
Advestra advised Novartis on the issuance of CHF 2.2 billion bonds, placed in five tranches as follows: UBS, BNP Paribas (Suisse) and Deutsche Bank Aktiengesellschaft acted as joint lead managers
Novartis AG, the Swiss multinational pharmaceutical corporation based in Basel, has appointed Alejandro Bes (pictured) as its global head of legal for the Immunology business unit. The lawyer steps into the role as his predecessor,
On October 4, 2023, Novartis successfully executed the spin-off of Sandoz by distributing Sandoz shares as a dividend-in-kind to Novartis shareholders and American Depositary Receipts (ADRs) holders. Sandoz shares are now listed on the SIX Swiss Exchange.
Bär & Karrer partner Daniel Hochstrasser (pictured) has been nominated for election to the Board of Directors of Novartis, a global healthcare company based in Switzerland, which will take place at the Annual General
